TAMPA, Fla., March 30, 2026
Concept Medical Inc. (CMI) announced the primary results of the SirPAD randomized controlled trial, demonstrating the safety and efficacy of its MagicTouch™ sirolimus-coated balloon in patients with peripheral arterial disease (PAD). The findings, presented as a Late-Breaking Clinical Trial at the ACC 2026 Scientific Sessions and published in the New England Journal of Medicine, represent a significant advancement in vascular intervention therapies, with potential to influence future clinical guidelines and treatment strategies for PAD.
Landmark Trial Demonstrates Superior Clinical Outcomes
The SirPAD trial is the largest randomized controlled study evaluating a sirolimus-coated balloon in PAD, enrolling 1,252 patients across a broad “all-comers” population, including individuals with femoropopliteal and below-the-knee disease. Patients were randomized to receive either the MagicTouch™ sirolimus-coated balloon or standard uncoated balloon angioplasty. At one year, the primary endpoint of major adverse limb events (MALE) occurred in 8.8% of patients in the sirolimus-coated balloon group compared to 15% in the control group, demonstrating both non-inferiority and statistical superiority.
Additionally, there was a significant reduction in secondary endpoints, including unplanned amputations and repeat revascularization procedures, highlighting the therapy’s clinical effectiveness in improving patient outcomes. These results establish strong evidence supporting sirolimus-based drug delivery in peripheral vascular disease, an area previously dominated by alternative drug technologies.
Innovative Drug-Coated Balloon Targets Treatment Resistance
Advertisement
The MagicTouch™ sirolimus-coated balloon represents a next-generation drug-device combination therapy, designed to deliver controlled, localized sirolimus release directly to diseased arteries, inhibiting smooth muscle cell proliferation and restenosis. Unlike earlier technologies, this approach addresses limitations associated with traditional angioplasty and certain drug-coated balloons, offering improved long-term vessel patency and reduced need for repeat interventions.
The SirPAD trial’s inclusive patient population, with nearly 50% of participants presenting with acute or chronic limb-threatening ischemia, provides robust evidence of effectiveness across complex and high-risk cases. This innovation reflects a broader shift toward precision-based interventional therapies, where localized drug delivery enhances both safety and therapeutic outcomes.
Clinical Evidence Positions Sirolimus Balloons as Future Standard
The SirPAD results build upon previous studies, including the SIRONA randomized trial, which demonstrated the non-inferiority of sirolimus-coated balloons compared to paclitaxel-based devices. With SirPAD now confirming superior clinical outcomes in a large-scale trial, sirolimus-coated balloons are increasingly positioned as a preferred treatment option in PAD management. Experts involved in the study emphasized that the “all-comers” design strengthens the generalizability of results, making the findings highly relevant for real-world clinical practice. The statistically significant reduction in adverse events and improved limb outcomes underscore the potential for this technology to reshape interventional cardiology and vascular surgery standards.
Advancing MedTech Innovation Under Clinical and Regulatory Standards
From a cGxP perspective, the SirPAD trial reflects strong adherence to Good Clinical Practice (GCP), with rigorous study design, independent oversight, and statistically robust endpoints. The development and evaluation of the sirolimus-coated balloon also involve strict quality and manufacturing controls under medical device regulatory frameworks, ensuring consistency, safety, and performance. The integration of drug and device technologies highlights the growing importance of combination products in modern healthcare, requiring advanced regulatory pathways and interdisciplinary expertise. As clinical evidence continues to accumulate, MagicTouch™ PTA is expected to play a key role in future regulatory approvals and guideline updates, reinforcing the importance of innovation-driven, evidence-based MedTech solutions in improving patient care.
Source: Concept Medical press release
